S Hooshmand1, M Kern2, D Metti2, P Shamloufard2, S C Chai3, S A Johnson4,5, M E Payton6, B H Arjmandi4,7. 1. School of Exercise and Nutritional Sciences, San Diego State University, 5500 Campanile Drive, San Diego, CA, 92182-7251, USA. shooshmand@mail.sdsu.edu. 2. School of Exercise and Nutritional Sciences, San Diego State University, 5500 Campanile Drive, San Diego, CA, 92182-7251, USA. 3. Department of Behavioral Health and Nutrition, University of Delaware, Newark, DE, USA. 4. Center for Advancing Exercise and Nutrition Research on Aging, Florida State University, Tallahassee, FL, USA. 5. Department of Food Science and Human Nutrition, Colorado State University, Fort Collins, CO, USA. 6. Department of Statistics, Oklahoma State University, Stillwater, OK, USA. 7. Department of Nutrition, Food and Exercise Sciences, Florida State University, Tallahassee, FL, USA.
Abstract
UNLABELLED: Daily consumption of 50 g of dried plum (equivalent to 5-6 dried plums) for 6 months may be as effective as 100 g of dried plum in preventing bone loss in older, osteopenic postmenopausal women. To some extent, these results may be attributed to the inhibition of bone resorption with the concurrent maintenance of bone formation. INTRODUCTION: The objective of our current study was to examine the possible dose-dependent effects of dried plum in preventing bone loss in older osteopenic postmenopausal women. METHODS:Forty-eight osteopenic women (65-79 years old) were randomly assigned into one of three treatment groups for 6 months: (1) 50 g of dried plum; (2) 100 g of dried plum; and (3) control. Total body, hip, and lumbar bone mineral density (BMD) were evaluated at baseline and 6 months using dual-energy X-ray absorptiometry. Blood biomarkers including bone-specific alkaline phosphatase (BAP), tartrate-resistant acid phosphatase (TRAP-5b), high-sensitivity C-reactive protein (hs-CRP), insulin-like growth factor-1 (IGF-1), and sclerostin were measured at baseline, 3 months, and 6 months. Osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), calcium, phosphorous, and vitamin D were measured at baseline and 6 months. RESULTS: Both doses of dried plum were able to prevent the loss of total body BMD compared with that of the control group (P < 0.05). TRAP-5b, a marker of bone resorption, decreased at 3 months and this was sustained at 6 months in both 50 and 100 g dried plum groups (P < 0.01 and P < 0.04, respectively). Although there were no significant changes in BAP for either of the dried plum groups, the BAP/TRAP-5b ratio was significantly (P < 0.05) greater at 6 months in both dried plum groups whereas there were no changes in the control group. CONCLUSIONS: These results confirm the ability of dried plum to prevent the loss of total body BMD in older osteopenic postmenopausal women and suggest that a lower dose of dried plum (i.e., 50 g) may be as effective as 100 g of dried plum in preventing bone loss in older, osteopenic postmenopausal women. This may be due, in part, to the ability of dried plums to inhibit bone resorption. This clinical trial was registered at ClinicalTrials.gov: NCT02325895 .
RCT Entities:
UNLABELLED: Daily consumption of 50 g of dried plum (equivalent to 5-6 dried plums) for 6 months may be as effective as 100 g of dried plum in preventing bone loss in older, osteopenic postmenopausal women. To some extent, these results may be attributed to the inhibition of bone resorption with the concurrent maintenance of bone formation. INTRODUCTION: The objective of our current study was to examine the possible dose-dependent effects of dried plum in preventing bone loss in older osteopenic postmenopausal women. METHODS: Forty-eight osteopenicwomen (65-79 years old) were randomly assigned into one of three treatment groups for 6 months: (1) 50 g of dried plum; (2) 100 g of dried plum; and (3) control. Total body, hip, and lumbar bone mineral density (BMD) were evaluated at baseline and 6 months using dual-energy X-ray absorptiometry. Blood biomarkers including bone-specific alkaline phosphatase (BAP), tartrate-resistant acid phosphatase (TRAP-5b), high-sensitivity C-reactive protein (hs-CRP), insulin-like growth factor-1 (IGF-1), and sclerostin were measured at baseline, 3 months, and 6 months. Osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), calcium, phosphorous, and vitamin D were measured at baseline and 6 months. RESULTS: Both doses of dried plum were able to prevent the loss of total body BMD compared with that of the control group (P < 0.05). TRAP-5b, a marker of bone resorption, decreased at 3 months and this was sustained at 6 months in both 50 and 100 g dried plum groups (P < 0.01 and P < 0.04, respectively). Although there were no significant changes in BAP for either of the dried plum groups, the BAP/TRAP-5b ratio was significantly (P < 0.05) greater at 6 months in both dried plum groups whereas there were no changes in the control group. CONCLUSIONS: These results confirm the ability of dried plum to prevent the loss of total body BMD in older osteopenic postmenopausal women and suggest that a lower dose of dried plum (i.e., 50 g) may be as effective as 100 g of dried plum in preventing bone loss in older, osteopenic postmenopausal women. This may be due, in part, to the ability of dried plums to inhibit bone resorption. This clinical trial was registered at ClinicalTrials.gov: NCT02325895 .
Entities:
Keywords:
Bone turnover biomarkers; Estrogen; Osteopenia; Osteoporosis; Prune
Authors: Shirin Hooshmand; Sheau C Chai; Raz L Saadat; Mark E Payton; Kenneth Brummel-Smith; Bahram H Arjmandi Journal: Br J Nutr Date: 2011-05-31 Impact factor: 3.718
Authors: M Franklin; S Y Bu; M R Lerner; E A Lancaster; D Bellmer; D Marlow; S A Lightfoot; B H Arjmandi; D J Brackett; E A Lucas; B J Smith Journal: Bone Date: 2006-08-04 Impact factor: 4.398
Authors: Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson Journal: J Bone Miner Res Date: 2007-03 Impact factor: 6.741
Authors: Bahram H Arjmandi; Dania A Khalil; Edralin A Lucas; Amanda Georgis; Barbara J Stoecker; Claudia Hardin; Mark E Payton; Robert A Wild Journal: J Womens Health Gend Based Med Date: 2002 Jan-Feb
Authors: S Y Bu; E A Lucas; M Franklin; D Marlow; D J Brackett; E A Boldrin; L Devareddy; B H Arjmandi; B J Smith Journal: Osteoporos Int Date: 2007-02-15 Impact factor: 5.071
Authors: Jennifer L Graef; Ping Ouyang; Yan Wang; Elizabeth Rendina-Ruedy; Megan R Lerner; Denver Marlow; Edralin A Lucas; Brenda J Smith Journal: J Funct Foods Date: 2018-01-30 Impact factor: 4.451
Authors: Mohammad Shahnazari; Russell T Turner; Urszula T Iwaniec; Thomas J Wronski; Min Li; Mario G Ferruzzi; Robert A Nissenson; Bernard P Halloran Journal: J Nutr Biochem Date: 2016-05-10 Impact factor: 6.048
Authors: Jennifer L Graef; Elizabeth Rendina-Ruedy; Erica K Crockett; Ping Ouyang; Jarrod B King; Robert H Cichewicz; Edralin A Lucas; Brenda J Smith Journal: J Nutr Biochem Date: 2017-09-29 Impact factor: 6.048